{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/prescribing-information/switching-antidepressants/","result":{"pageContext":{"chapter":{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants","depth":2,"htmlHeader":"<!-- begin field ea6648cc-5e88-4716-8f5f-a7070101fc71 --><h2>How should I switch from one antidepressant to another?</h2><!-- end field ea6648cc-5e88-4716-8f5f-a7070101fc71 -->","summary":"","htmlStringContent":"<!-- begin item 06350963-1d8a-4348-ae37-a7070101fb1e --><!-- begin field 9846c6bf-df2e-44b7-a8b0-a7070101fc71 --><ul><li>When switching from one antidepressant to another, be aware of the need for gradual and modest increases of dose, interactions between antidepressants, and the risk of serotonin syndrome when combinations of serotonergic antidepressants are prescribed. Features of serotonin syndrome include confusion, delirium, shivering, sweating, changes in blood pressure, and myoclonus.<ul><li>Most severe cases of serotonin syndrome involve an MAOI (including moclobemide) and an SSRI.  </li></ul></li><li>Abrupt withdrawal should generally be avoided when switching from one antidepressant to another. </li><li>Cross tapering is usually preferred (an example of a cross-tapering regimen is shown in Table 1). However, in some instances it may be possible to withdraw the current antidepressant and start the new antidepressant on the next day, for example when switching from one serotonin reuptake inhibitor (SSRI) to another SSRI or a serotonin norepinephrine reuptake inhibitor (SNRI); the exception to this is fluoxetine.<p><strong>Table 1.</strong> An example of a cross-tapering regimen — switching from citalopram to mirtazapine.</p><table data-table-id=\"ad8ea39d-698b-4342-9479-acce014f77b8\"><thead><tr><th scope=\"col\"> </th><th scope=\"col\">Pre-switch dosage</th><th scope=\"col\">Week 1</th><th scope=\"col\">Week 2</th><th scope=\"col\">Week 3</th><th scope=\"col\">Week 4</th></tr></thead><tbody><tr><td><strong>Withdrawing citalopram</strong></td><td>40 mg daily</td><td>20 mg daily</td><td>10 mg daily</td><td>nil</td><td>nil</td></tr><tr><td><strong>Introducing mirtazapine</strong></td><td>Nil</td><td>15 mg daily</td><td>30 mg daily</td><td>30 mg daily</td><td>45 mg daily (if required)</td></tr><tr><td colspan=\"6\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]</td></tr></tbody></table></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><!-- end field 9846c6bf-df2e-44b7-a8b0-a7070101fc71 --><!-- end item 06350963-1d8a-4348-ae37-a7070101fb1e -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a2ddb7cf-56d6-5fe3-8fd3-be6d1c0bb00a","slug":"from-a-tca","fullItemName":"From a TCA","depth":3,"htmlHeader":"<!-- begin field e5581a79-d27e-49b2-a2e4-a707010311ef --><h3>Switching from a TCA to different TCA or to another type of antidepressant</h3><!-- end field e5581a79-d27e-49b2-a2e4-a707010311ef -->","summary":"","htmlStringContent":"<!-- begin item d1ebafa0-6262-4423-b20e-a707010310e1 --><!-- begin field 08b56c5c-4e09-41c7-bf60-a707010311ef --><ul><li>Cross-tapering with a tricyclic antidepressant (TCA) is inadvisable with paroxetine and fluvoxamine — if necessary it should be done very cautiously [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].  </li><li>Clomipramine is a potent inhibitor of serotonin reuptake and serotonin syndrome is more likely if co-administered with an SSRI or SNRI — cross-tapering is not recommended except under specialist supervision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].  <ul><li>Clomipramine should be withdrawn before starting a selective serotonin reuptake inhibitor (SSRI) or selective serotonin and noradrenaline reuptake inhibitor (SNRI) and vice versa.</li></ul></li><li>Be aware that interactions with fluoxetine may still occur for 5 weeks after stopping fluoxetine because of its long half-life.</li></ul><p><strong>Table 1.</strong> Switching antidepressants.</p><table><thead><tr><th scope=\"col\"> </th><th colspan=\"8\" rowspan=\"1\" scope=\"col\">Switching to:</th></tr><tr><th scope=\"col\">Switching from:</th><th scope=\"col\"> TCA (except clomipramine)</th><th scope=\"col\">SSRI ( citalopram, escitalopram, paroxetine or sertraline)</th><th scope=\"col\">SNRI (duloxetine, venlafaxine)</th><th scope=\"col\">Fluoxetine</th><th scope=\"col\">Mirtazapine</th><th scope=\"col\">Moclobemide</th><th scope=\"col\">Reboxetine</th><th scope=\"col\">Trazodone</th></tr></thead><tbody><tr><td> TCA (except clomipramine)</td><td>Direct switch possible</td><td><p>Gradually reduce the dose of TCA to 25–50 mg daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>] or half the usual dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]. Start SSRI then slowly withdraw TCA over next 5–7 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>]</p></td><td>Cross-taper cautiously starting with low dose SNRI</td><td>Halve dose of TCA, add fluoxetine and then slowly withdraw TCA</td><td>Cross-taper cautiously</td><td>Taper then stop TCA, then wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Halve dose of TCA, add trazodone and then slowly withdraw TCA</td></tr><tr><td>SSRIs ( citalopram, escitalopram, paroxetine or sertraline)</td><td><p>Cross-taper cautiously with low dose of TCA</p></td><td>Direct switch possible</td><td>Direct switch possible (caution if paroxetine used)</td><td>Direct switch possible</td><td>Cross-taper cautiously</td><td>Taper then stop SSRI, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>SNRIs (duloxetine, venlafaxine)</td><td>Cross-taper cautiously with low dose of TCA</td><td>Direct switch possible</td><td>Direct switch possible</td><td>Direct switch possible</td><td>Cross-taper cautiously</td><td>Taper then stop SNRI, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>Fluoxetine</td><td>Stop fluoxetine, start TCA at a low dose 4–7 days later and increase dose very slowly</td><td>Stop fluoxetine, start SSRI at a low dose 4–7 days later</td><td>Stop fluoxetine, start SSRI at a low dose 4–7 days later</td><td>—</td><td>Cross-taper cautiously</td><td>Stop fluoxetine then wait for 5–6 weeks then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>Mirtazapine</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>—</td><td>Taper then stop mirtazapine, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>—</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td></tr><tr><td>Reboxetine</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Taper then stop reboxetine, wait for 1 week then start moclobemide</td><td>—</td><td>Cross-taper cautiously</td></tr><tr><td>Trazodone</td><td>Cross-taper cautiously with low dose of TCA</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Taper then stop trazodone, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>—</td></tr><tr><td colspan=\"9\"><strong>Sources: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>]</td></tr></tbody></table><!-- end field 08b56c5c-4e09-41c7-bf60-a707010311ef --><!-- end item d1ebafa0-6262-4423-b20e-a707010310e1 -->","subChapters":[]},{"id":"7c031656-391f-57a9-a8ab-3a747e5b65a6","slug":"from-trazodone","fullItemName":"From trazodone","depth":3,"htmlHeader":"<!-- begin field 1d527ac8-86dc-4732-a6f2-a70701033171 --><h3>Switching from trazodone to another antidepressant</h3><!-- end field 1d527ac8-86dc-4732-a6f2-a70701033171 -->","summary":"","htmlStringContent":"<!-- begin item aa3e8063-e1dd-40f5-8474-a70701033007 --><!-- begin field 9482973b-8ae1-4df9-bfa0-a70701033171 --><table data-table-id=\"2a6e2c6c-852c-4343-b91e-acce014f7551\"><thead><tr><th scope=\"col\"><strong>Switching from trazodone to:</strong></th><th scope=\"col\"><strong>Method</strong></th></tr></thead><tbody><tr><td>A TCA (except clomipramine)</td><td>Cross-taper cautiously with a low dose of TCA</td></tr><tr><td>SSRIs: citalopram, escitalopram, paroxetine or sertraline</td><td>Cross-taper cautiously</td></tr><tr><td>SNRIs: duloxetine, venlafaxine</td><td>Cross-taper cautiously</td></tr><tr><td>Fluoxetine</td><td>Cross-taper cautiously</td></tr><tr><td>Mirtazapine</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td>Taper trazodone, then stop. Wait for 1 week then start moclobemide</td></tr><tr><td>Reboxetine</td><td>Cross-taper cautiously</td></tr><tr><td colspan=\"2\"><strong>Source: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]</td></tr></tbody></table><!-- end field 9482973b-8ae1-4df9-bfa0-a70701033171 --><!-- end item aa3e8063-e1dd-40f5-8474-a70701033007 -->","subChapters":[]},{"id":"5d2280e6-0f42-5de8-8a59-aca71d7f62fb","slug":"from-ssri","fullItemName":"From SSRI","depth":3,"htmlHeader":"<!-- begin field 27cbbf1d-d720-44b8-8e2a-a7070103f3e6 --><h3>Switching from citalopram, escitalopram, sertraline, or paroxetine to another antidepressant</h3><!-- end field 27cbbf1d-d720-44b8-8e2a-a7070103f3e6 -->","summary":"","htmlStringContent":"<!-- begin item 6c2ad1ec-4509-4e02-8c3d-a7070103f2a9 --><!-- begin field da986a3f-015a-4e7c-96cb-a7070103f3e6 --><ul><li>Cross-tapering with a tricyclic antidepressant (TCA) is inadvisable with paroxetine and fluvoxamine — if necessary it should be done very cautiously [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].  </li><li>Clomipramine is a potent inhibitor of serotonin reuptake and serotonin syndrome is more likely if co-administered with an SSRI or SNRI — cross-tapering is not recommended except under specialist supervision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].  <ul><li>Clomipramine should be withdrawn before starting an SSRI or SNRT and vice versa.</li></ul></li></ul><table data-table-id=\"3556fff6-e939-4312-911c-acce014f759f\"><thead><tr><th scope=\"col\"><strong>Switching from citalopram, escitalopram, sertraline, or paroxetine to:</strong></th><th scope=\"col\"><strong>Method</strong></th></tr></thead><tbody><tr><td>A TCA (except clomipramine)</td><td>Cross-taper cautiously with a low dose of TCA</td></tr><tr><td>SSRIs: citalopram, escitalopram, sertraline, or paroxetine</td><td>Direct switch possible</td></tr><tr><td>SNRIs: duloxetine, venlafaxine</td><td>Direct switch possible (caution if paroxetine used)</td></tr><tr><td>Fluoxetine</td><td>Direct switch possible</td></tr><tr><td>Mirtazapine</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td>Taper then stop, wait for 1 week then start moclobemide</td></tr><tr><td>Reboxetine</td><td>Cross-taper cautiously</td></tr><tr><td>Trazodone</td><td>Cross-taper cautiously</td></tr><tr><td colspan=\"2\"><strong>Sources: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>]</td></tr></tbody></table><!-- end field da986a3f-015a-4e7c-96cb-a7070103f3e6 --><!-- end item 6c2ad1ec-4509-4e02-8c3d-a7070103f2a9 -->","subChapters":[]},{"id":"af930c7d-a3b7-592e-8bca-bf9adc1ad7b5","slug":"from-fluoxetine","fullItemName":"From fluoxetine","depth":3,"htmlHeader":"<!-- begin field b07c5e2e-3dce-4b3d-8bf3-a70701041996 --><h3>Switching from fluoxetine to another antidepressant</h3><!-- end field b07c5e2e-3dce-4b3d-8bf3-a70701041996 -->","summary":"","htmlStringContent":"<!-- begin item 0fb3b0c8-c96f-4621-a416-a7070104184e --><!-- begin field 2e008718-1120-4226-9f26-a70701041996 --><ul><li><strong>Be aware that interactions with fluoxetine may still occur for 5 weeks after stopping fluoxetine because of its long half-life.</strong></li></ul><table data-table-id=\"1730578a-5731-4682-aa22-acce014f75df\"><thead><tr><th scope=\"col\"><strong>Switching from fluoxetine to:</strong></th><th scope=\"col\"><strong>Method</strong></th></tr></thead><tbody><tr><td>A TCA (except clomipramine)</td><td>Stop fluoxetine, start TCA at a low dose 4–7 days later and increase dose very slowly</td></tr><tr><td>SSRIs: citalopram, escitalopram, sertraline, or paroxetine</td><td>Stop fluoxetine, start SSRI at a low dose 4–7 days later</td></tr><tr><td>SNRIs: duloxetine, venlafaxine</td><td>Stop fluoxetine, start SNRI at a low dose 4–7 days later</td></tr><tr><td>Mirtazapine</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td><p>Stop fluoxetine then wait for 5–6 weeks then start moclobemide</p></td></tr><tr><td>Reboxetine</td><td>Cross-taper cautiously</td></tr><tr><td>Trazodone</td><td>Cross-taper cautiously</td></tr><tr><td colspan=\"2\"><strong>Sources: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]</td></tr></tbody></table><!-- end field 2e008718-1120-4226-9f26-a70701041996 --><!-- end item 0fb3b0c8-c96f-4621-a416-a7070104184e -->","subChapters":[]},{"id":"ba2f2e1f-2e0b-530f-b23d-d0dacd3dfc04","slug":"from-mirtazapine","fullItemName":"From mirtazapine","depth":3,"htmlHeader":"<!-- begin field 530aac06-d906-415c-b80d-a707010440bd --><h3>Switching from mirtazapine to another antidepressant</h3><!-- end field 530aac06-d906-415c-b80d-a707010440bd -->","summary":"","htmlStringContent":"<!-- begin item 24f5ecc8-0673-417a-81e7-a70701043a84 --><!-- begin field 79679dc7-0406-4195-b9ce-a707010440bd --><table data-table-id=\"c5aca043-d632-42bb-a6c3-acce014f7619\"><thead><tr><th scope=\"col\"><strong>Switching from mirtazapine to:</strong></th><th scope=\"col\"><strong>Method</strong></th></tr></thead><tbody><tr><td>A TCA (except clomipramine)</td><td>Cross-taper cautiously</td></tr><tr><td>SSRIs: citalopram, escitalopram, sertraline, or paroxetine</td><td>Cross-taper cautiously</td></tr><tr><td>SNRIs: duloxetine, venlafaxine</td><td>Cross-taper cautiously</td></tr><tr><td>Fluoxetine</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td><p>Taper then stop mirtazapine, wait for 1 week then start moclobemide</p></td></tr><tr><td>Reboxetine</td><td>Cross-taper cautiously</td></tr><tr><td>Trazodone</td><td>Cross-taper cautiously</td></tr><tr><td colspan=\"2\"><strong>Sources: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]</td></tr></tbody></table><!-- end field 79679dc7-0406-4195-b9ce-a707010440bd --><!-- end item 24f5ecc8-0673-417a-81e7-a70701043a84 -->","subChapters":[]},{"id":"73079259-1746-5076-9d7b-6e452cc961bf","slug":"from-reboxetine","fullItemName":"From reboxetine","depth":3,"htmlHeader":"<!-- begin field 88a9ce39-837a-4ac7-8825-a70f00b84ec8 --><h3>Switching from reboxetine to another antidepressant</h3><!-- end field 88a9ce39-837a-4ac7-8825-a70f00b84ec8 -->","summary":"","htmlStringContent":"<!-- begin item 22cc4952-b97d-4c4c-9689-a70f00b84f4a --><!-- begin field b89c5b3e-0a9e-4444-841a-a70f00b84ec8 --><table data-table-id=\"069c4d5d-e3df-4085-8c0b-acce014f7854\"><thead><tr><th scope=\"col\"><strong>Switching from reboxetine to:</strong></th><th scope=\"col\"><strong>Method</strong></th></tr></thead><tbody><tr><td>A TCA (except clomipramine)</td><td>Cross-taper cautiously</td></tr><tr><td>SSRIs: citalopram, escitalopram, sertraline, or paroxetine</td><td>Cross-taper cautiously</td></tr><tr><td>SNRIs: duloxetine, venlafaxine</td><td>Cross-taper cautiously</td></tr><tr><td>Fluoxetine</td><td>Cross-taper cautiously</td></tr><tr><td>Mirtazapine</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td><p>Taper then stop reboxetine, wait for 1 week then start moclobemide</p></td></tr><tr><td>Trazodone</td><td>Cross-taper cautiously</td></tr><tr><td colspan=\"2\"><strong>Sources: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]</td></tr></tbody></table><!-- end field b89c5b3e-0a9e-4444-841a-a70f00b84ec8 --><!-- end item 22cc4952-b97d-4c4c-9689-a70f00b84f4a -->","subChapters":[]},{"id":"5c835bb6-00f9-53f1-9d69-e68a5dcb8294","slug":"from-moclobemide","fullItemName":"From moclobemide","depth":3,"htmlHeader":"<!-- begin field 067eea69-c6b5-4f71-b086-a70f00b83215 --><h3>Switching from moclobemide to another antidepressant</h3><!-- end field 067eea69-c6b5-4f71-b086-a70f00b83215 -->","summary":"","htmlStringContent":"<!-- begin item cea4c2bc-97cd-48ea-b78c-a70f00b8324c --><!-- begin field 9ebeaa0a-107b-440b-994e-a70f00b83215 --><ul><li><strong>When switching from moclobemide to another antidepressant: </strong><ul><li>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>] </p><!-- end field 9ebeaa0a-107b-440b-994e-a70f00b83215 --><!-- end item cea4c2bc-97cd-48ea-b78c-a70f00b8324c -->","subChapters":[]},{"id":"5b062d36-2dfa-5269-ac2a-53c76717085e","slug":"from-snri","fullItemName":"From SNRI","depth":3,"htmlHeader":"<!-- begin field cbee94dc-1229-4be7-a62b-a70f00b87674 --><h3>Switching from duloxetine or venlafaxine to another antidepressant</h3><!-- end field cbee94dc-1229-4be7-a62b-a70f00b87674 -->","summary":"","htmlStringContent":"<!-- begin item 56315b78-22cd-4b6e-bcf7-a70f00b876b9 --><!-- begin field 77b9a55f-8e3f-43ec-8a3a-a70f00b87674 --><ul><li>Clomipramine is a potent inhibitor of serotonin reuptake and serotonin syndrome is more likely if co-administered with an SSRI or SNRI — cross-tapering is not recommended except under specialist supervision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].  <ul><li>Clomipramine should be withdrawn before starting an SSRI or SNRI and vice versa.</li></ul></li></ul><table data-table-id=\"84cfc2e4-0df4-460e-9e0c-acce014f789f\"><thead><tr><th scope=\"col\"><strong>Switching from duloxetine or venlafaxine to:</strong></th><th scope=\"col\"><strong>Method</strong></th></tr></thead><tbody><tr><td>A TCA (except clomipramine)</td><td>Cross-taper cautiously with a low dose of TCA</td></tr><tr><td>SSRIs: citalopram, escitalopram, sertraline, or paroxetine</td><td>Direct switch possible</td></tr><tr><td>SNRIs: duloxetine, venlafaxine</td><td>Direct switch possible</td></tr><tr><td>Mirtazapine</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td><p>Taper then stop duloxetine, wait for 1 week then start moclobemide</p></td></tr><tr><td>Reboxetine</td><td>Cross-taper cautiously</td></tr><tr><td>Trazodone</td><td>Cross-taper cautiously</td></tr><tr><td colspan=\"2\"><strong>Sources: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]</td></tr></tbody></table><!-- end field 77b9a55f-8e3f-43ec-8a3a-a70f00b87674 --><!-- end item 56315b78-22cd-4b6e-bcf7-a70f00b876b9 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}